Cangrelor versus no cangrelor during percutaneous coronary intervention in hemodynamically unstable patients: a cohort study on benefits and risks

30 August 2024 (12:50 - 13:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Mr Oskar Love Emilsson

Skane University Hospital, Lund (Sweden)

5 More presentations in this session

Presentation thumbnail

P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis

Doctor M. Galli (Rome, IT)

Abstract Slides Video

Presentation thumbnail

Clopidogrel versus aspirin monotherapy for secondary prevention after percutaneous coronary intervention - a nationwide population-based study

Mr J. Cho (Seoul, KR)

Abstract Slides Video

Presentation thumbnail

Implementation of prasugrel and prognostic outcomes after percutaneous coronary intervention for myocardial infarction: a nationwide observational study

Doctor M. Jacobsen (Copenhagen, DK)

Abstract Slides Video

Presentation thumbnail

Impact of different P2Y12 inhibitors in acute coronary syndrome patients with severe chronic kidney disease: insights from the CORALYS registry

Doctor F. Giacobbe (Turin, IT)

Abstract Slides Video

Presentation thumbnail

Pretreatment with dual antiplatelet therapy in acute myocardial infarction

Professor Z. Motovska (Prague, CZ)

Abstract Slides Video

Access the full session

Session thumbnail

Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention

The Event

Event poster

ESC Congress 2024

30 August 2024 12:50 CET

You may be interested in

Congress Presentation

Paradigm shift in PCI with cardiogenic shock

Congress Presentation

P2Y12-inhibition in acute myocardial infarction with cardiogenic shock

Congress Presentation

Discussant review - DAPT-SHOCK-AMI

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources